

# CYSTIC FIBROSIS – KALYDECO/ORKAMBI/SYMDEKO/TRIKAFTA

## PRIOR AUTHORIZATION REQUEST

### PRESCRIBER FAX FORM

**ONLY the prescriber may complete and fax this form. This form is for prospective, concurrent, and retrospective reviews.**

**Incomplete forms will be returned for additional information.** The following documentation is required for prior authorization consideration. For formulary information and to download additional forms, please visit [https://www.bcbstx.com/provider/medicaid/rx\\_prior\\_auth.html](https://www.bcbstx.com/provider/medicaid/rx_prior_auth.html)

#### PATIENT AND INSURANCE INFORMATION

Today's Date: \_\_\_\_\_

Patient Name (First):	Last:	M:	DOB (mm/dd/yy):	
Patient Address:		City, State, Zip:		Patient Telephone:
BCBSTX ID Number:		Group Number:		

#### PRESCRIBER/CLINIC INFORMATION

Prescriber Name:	Prescriber NPI#:	Specialty:	Contact Name:
Clinic Name:		Clinic Address:	
City, State, Zip:		Phone #:	Secure Fax #:

#### PLEASE ATTACH ANY ADDITIONAL INFORMATION THAT SHOULD BE CONSIDERED WITH THIS REQUEST

Patient's Diagnosis- ICD code plus description: \_\_\_\_\_

Medication Requested: \_\_\_\_\_ Strength: \_\_\_\_\_

Dosing Schedule: \_\_\_\_\_ Quantity per Month: \_\_\_\_\_

1. Is the patient currently treated with the requested medication?..... Yes  No  
**If yes**, when was treatment with the requested medication started? \_\_\_\_\_

2. Does the patient have any of the following gene mutations in the CFTR gene? (check all that apply):  
 A1067T  A455E  D110E  D110H  D1152H  D1270N  D579G  E193K  
 E56K  F1052V  F1074L  G1069R  G1244E  G1349D  G178R  G551D  
 G551S  K1060T  L206W  P67L  R1070Q  R1070W  R117C  R117H  
 R347H  R352Q  R74W  S1251N  S1255P  S549N  S549R  3272-26A  
 S977F  S945L  2789+5G  711+3A  E821X  E831X  3849+10kbC  
 711+3A-G  2789+5G-A  3272-26A-G  3849+10dkC-T  
 Other (Please specify): \_\_\_\_\_

3. Does the patient have the presence of the following F508del mutations of the CFTR gene confirmed by genetic testing? ..... Yes  No  
 Heterozygous (one allele)  Homozygous (BOTH alleles)

4. Please list the medications the patient has **previously tried and failed for treatment of this diagnosis**. (Please specify if brand name, generic, extended-release products, or over-the-counter products.)  
\_\_\_\_\_  
Date(s): \_\_\_\_\_ Date(s): \_\_\_\_\_  
\_\_\_\_\_  
Date(s): \_\_\_\_\_ Date(s): \_\_\_\_\_  
\_\_\_\_\_  
Date(s): \_\_\_\_\_ Date(s): \_\_\_\_\_

5. Please list all reasons for selecting the **requested medication** over alternatives (e.g., contraindications, allergies or history of adverse drug reactions, lower doses tried). \_\_\_\_\_

6. Please list all other medications the patient will be taking **in combination** with the requested medication for this diagnosis. \_\_\_\_\_

#### For Trikafta Requests

7. Has the patient been diagnosed with severe hepatic impairment in the last 365 days?..... Yes  No

Prescriber or Authorized Signature: \_\_\_\_\_

Date: \_\_\_\_\_

*Prior Authorization of Benefits is not the practice of medicine or the substitute for the independent medical judgment of a treating physician. Only a treating physician can determine what medications are appropriate for a patient. Please refer to the applicable plan for the detailed information regarding benefits, conditions, limitations, and exclusions. The submitting provider certifies that the information provided is true, accurate, and complete and the requested services are medically indicated and necessary to the health of the patient.*

Note: Payment is subject to member eligibility Authorization does not guarantee payment.

#### Please fax or mail this form to:

Prime Therapeutics LLC, Clinical Review Department  
2900 Ames Crossing Road  
Eagan, Minnesota 55121

#### TOLL FREE

Fax: 877.243.6930 Phone: 855.457.0407

**CONFIDENTIALITY NOTICE:** This communication is intended only for the use of the individual entity to which it is addressed and may contain information that is privileged or confidential. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please notify the sender immediately by telephone at 866.202.3474 and return the original message to Prime Therapeutics via U.S. Mail. Thank you for your cooperation.